Drug may curb bleeding in radical pelvic surgery
NCT ID NCT03128866
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if tranexamic acid, a drug that helps blood clots stay stable, can reduce bleeding in patients having hemipelvectomy surgery for pelvic tumors. About 80 adults and children with pelvic tumors will take part. The goal is to see if the drug lowers the amount of blood lost during and after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
80 people
The number who actually took part.
- Started
-
May 2017
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Both pediatric and adult patients can be eligible to participate * Cognitively impaired and non-English speakers can be eligible to participate. * Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption Exclusion Criteria: * Patient with a history of genetic prothrombotic state * Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis * Patients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstruction * Female patients will not be eligible for this study if she is either pregnant or nursing at the time of enrollment * Patients will not be eligible if they have a history of color vision defects * Patients will not be eligible if they have a history of retinal vein or artery occlusion * Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months * Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid * Patients will not be eligible if they present with moderate to severe decrease in creatinine clearance (estimated glomerular filtration rate \[eGFR\] \< 45 mL/min/1.73m2) * Patients will not be eligible if they present or have a history of seizure disorder
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pelvic mass are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States